CryoStor® and Hematopoietic Stem and Progenitor Cells (HSPC)

Print Friendly

ATCC Application Note No. 16 describes protocols for the isolation and purification of bone marrow-derived (BM) CD34+ cells cryopreserved in CryoStor® CS10. Post-thaw viability was greater than 95% measured by flow cytometry for BM CD34+ cells cryopreserved in CS10, rapidly thawed and transferred to Hank’s Balanced Salt Solution + 10% Fetal Bovine Serum. Following washing and transfer to media for differentiation and expansion, CS10-cryopreserved BM CD34+ cells exhibited high viability and lineage-specific, total nucleated cell (TNC) expansion of 550-fold for erythroid lineage precursor cells (>90% erythroid marker positive, <20% CD34+) , 66-fold for megakaryocyte lineage precursor cells (>90% megakaryocyte marker positive, <5% CD34+), and >1000-fold for myeloid lineage precursor cells (70% pan-myeloid marker positive, <5% CD34+).

See additional CryoStor® and cryopreservation journal articles.

BioLife Customer Capricor Therapeutics Initiates the DYNAMIC Clinical Trial for the Treatment of Advanced Heart Failure

BioLife Customer Bellicum Pharma (BLCM) Completes Dosing of First Cohort in BP-004

Biopreservation of Hair Transplant Grafts using HypoThermosol®

Print Friendly

Storage of Hair Transplant Grafts outside of the body significantly impacts the quality of hair transplant procedures.

There are almost as many opinions on the best ex vivo storage media for follicle grafts during a hair transplant procedure as there are hair transplant surgeons.

Many surgeons have used the same protocol for years with great success, and there is always a tendency not to ‘rock the boat’ or mess with something that has worked in the past. But is your chosen hair graft storage solution as good as it could be? And how much impact does storage media have on the final quality of a transplant operation?

Which storage media offers the greatest protection to grafts during hair transplantation?

HypoThermosol, hair transplant, graft, ex vivo storage solution

Follicular unit growth following hair transplant

In a recent article for Hair Transplant International, renowned biopreservation expert Aby J. Mathew, Ph.D., argues that optimized intracellular-like solutions (such as HypoThermosol® FRS) are the best option for supporting grafts during ex vivo storage.

Dr. Mathew argues that these solutions offer the greatest level of protection and the lowest level of stress on the graft during its time outside of the body. This reduced stress increases the probability for improved survival and growth of follicular units post-transplantation, as can been seen in the image on the right.

How does an intracellular-like solution improve graft viability?

Most hair graft storage solutions in wide spread use represent ‘isotonic solutions’ composed of simple saline and modified cell culture media (Plasma-Lyte®, Lactated ringers®, DMEM, or Williams E), and were originally designed to support cells at normal body temperatures. Hair transplant grafts however are routinely stored in a hypothermic state (typically 2-8 °C) in order to reduce metabolic demand and gain the beneficial, protective effects of reduced temperature on the cells and tissues of the graft.

Unfortunately, the very same characteristics of hypothermia that confer graft protection also result in inactivation of the ATP-driven ion pumps that would normally maintain osmotic balance, leading to changes in cell membranes, instability of intracellular structures, free radical generation, abnormal water flux, and ultimately, cell death via apoptosis, necrosis, and/or secondary necrosis 8-21. These factors are all exacerbated in isotonic solutions that mimic the cells extracellular environment. While well suited to supporting an active cell at normal body temperature (where metabolic rates are normal and ATP-driven ion pumps are operational), isotonic solutions will actually accelerate the process of cell edema, lysis, and death under the hypothermic conditions experienced by hair grafts during ex vivo storage.

Maximizing the viability of hair transplant grafts following ex vivo storage.

To support a cell under hypothermic conditions and in order to reap maximum benefit from the stasis conferred by reduced temperature, we need a solution that maintains a balanced intracellular environment. An optimized intracellular-like solution (such as HypoThermosol® FRS) is formulated specifically to support tissue samples during hypothermic storage, and address the stresses of hypothermia with balanced ions and molecules, targeted pH buffering, and potent free radical scavengers that reduce hair follicle cell death via apoptosis and necrosis. Such a solution works to mitigate the overall cell stresses, buffering cells in each follicular unit, and increasing the potential for stronger and more rapid recovery of the graft post-transplantation.

The increased cell viability of tissue samples stored in an optimized intracellular-like solution versus those samples stored in a variety of isotonic solutions is clearly visible under fluorescent microscopy (figure 2 below).

Fig. 2. Fluorescent micrographs illustrating cell viability following hypothermic ex vivo storage in different storage solutions.

Hypothermosol, hair transplant, ex vivo storage solution

Recovery of viable cells following hypothermic storage in HypoThermosol compared to other storage media

Enhancing the health and viability of the follicular unit grafts is essential to ensure the quality and success of a hair transplant procedure as measured by graft survival, hairline design, graft density, scalp irritation/edema, rate of regrowth, and hair shaft thickness. The optimization of ex vivo storage conditions is a practical and effective way to improve the health and viability of the follicular unit grafts.

You can read the full article by Dr Aby J. Mathew, and learn more about benefits of HypoThermosol for hair transplantation. For references cited in this review, please see the main article.

CryoStor® Cited in AABB 2014 Top Poster

Print Friendly

2014 BEST 65 POSTERT-cells frozen in CryoStor CS5 and CS10 exhibit post-thaw viability, proliferative response, and cytotoxic cytokine profiles similar to that of freshly isolated cells. Please click on image to view the full poster pdf.
See additional cryopreservation posters.

BioLife Solutions Makes Deloitte’s 2014 Technology Fast 500TM List Again

Print Friendly


Fast500BioLife Solutions has been named to the Deloitte 2014 Technology Fast 500 List, a ranking of the fastest growing technology, media, telecommunications, life sciences and clean technology companies in North America. This is the second consecutive year BioLife has been recognized for high growth. BioLife President & CEO, Mike Rice, attributes the Company’s success to an innovative, customer-focused philosophy, and highly dedicated employees.

The entire BioLife team is honored to be included in this year’s list along with many other impressive technology companies.

Read more..

HypoThermosol® FRS and Cold-Chain Supply Solutions

Print Friendly

In a recent GMP Review article (Vol 13, No. 2 July 2014), The maturing world of ATMP manufacture, by Drew Hope, HypoThermosol® FRS was cited as a promising short-term, cryopreservation-free, cold-chain supply solution. HypoThermosol’s high osmotic concentrations and free-radical scavenging properties provide cold stability (2-8° C) for several days, and is currently being used in over 130 customer clinical trials.

BioLife Solutions Announces Manufacturing Agreement With Somahlution LLC

Print Friendly

Under terms of a three-year agreement with Somahlution LLC, a Jupiter, Florida-based biotechnology company, BioLife will manufacture DuraGraft, a tissue preservation solution for storage of harvested veins used in coronary artery bypass graft (CABG) and other vascular access surgeries. Unlike existing potentially cytocidal and clinically-unproven solutions, DuraGraft is the first Endothelial Damage Inhibitor (EDI) that uniquely protects vascular endothelium and its associated architecture.

Read the entire press release.

BioLife Solutions Receives Biopreservation Media Technology Innovation Leadership Award

Print Friendly


BioLife Solutions announced on June 11th, 2014, that it received Frost & Sullivan’s 2014 North American Biopreservation Media Technology Innovation Leadership Award.
The award is given to a Biotech company that has demonstrated a commitment to innovation, commercialization success, application diversity, and fulfillment of unmet needs in the company’s strategic markets. Please see entire press release.
Frost & Sullivan Award


BioLife Solutions’ Cryopreservation Technology vs ‘Home-Brewed Cocktails’

Print Friendly

BioLife Solutions’ clinical grade biopreservation media continues to gain adoption over traditional “home-brew” reagent cocktails, according to a recent article in Please see Cell-based drugs drive cryo-freeze tech over ‘home-brewed cocktails’.

In related news released last week, BioLife Solutions announced that Natick, Massachusetts-based Parcell Laboratories has adopted BioLife’s CryoStor clinical grade cell and tissue freeze media for use in future clinical trials of Early Lineage Adult (ELA) stem cell-potential therapies, for which Parcell holds an exclusive worldwide license. Please see BioLife Solutions CryoStor® Freeze Media Adopted by Parcell Laboratories for Stem Cells to be Studied in Clinical Trials.